全文获取类型
收费全文 | 26638篇 |
免费 | 2178篇 |
国内免费 | 67篇 |
专业分类
耳鼻咽喉 | 390篇 |
儿科学 | 732篇 |
妇产科学 | 570篇 |
基础医学 | 3423篇 |
口腔科学 | 295篇 |
临床医学 | 2710篇 |
内科学 | 5529篇 |
皮肤病学 | 530篇 |
神经病学 | 2526篇 |
特种医学 | 1269篇 |
外科学 | 4265篇 |
综合类 | 292篇 |
一般理论 | 23篇 |
预防医学 | 2028篇 |
眼科学 | 477篇 |
药学 | 1892篇 |
1篇 | |
中国医学 | 24篇 |
肿瘤学 | 1907篇 |
出版年
2023年 | 259篇 |
2022年 | 176篇 |
2021年 | 945篇 |
2020年 | 644篇 |
2019年 | 983篇 |
2018年 | 1074篇 |
2017年 | 733篇 |
2016年 | 756篇 |
2015年 | 966篇 |
2014年 | 1199篇 |
2013年 | 1546篇 |
2012年 | 2233篇 |
2011年 | 2279篇 |
2010年 | 1230篇 |
2009年 | 979篇 |
2008年 | 1520篇 |
2007年 | 1543篇 |
2006年 | 1435篇 |
2005年 | 1282篇 |
2004年 | 1128篇 |
2003年 | 974篇 |
2002年 | 877篇 |
2001年 | 334篇 |
2000年 | 239篇 |
1999年 | 272篇 |
1998年 | 161篇 |
1997年 | 119篇 |
1996年 | 119篇 |
1995年 | 93篇 |
1994年 | 78篇 |
1993年 | 81篇 |
1992年 | 171篇 |
1991年 | 163篇 |
1990年 | 175篇 |
1989年 | 164篇 |
1988年 | 130篇 |
1987年 | 126篇 |
1986年 | 129篇 |
1985年 | 129篇 |
1984年 | 108篇 |
1983年 | 94篇 |
1982年 | 62篇 |
1981年 | 85篇 |
1980年 | 68篇 |
1979年 | 97篇 |
1978年 | 73篇 |
1975年 | 65篇 |
1974年 | 64篇 |
1973年 | 70篇 |
1972年 | 71篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
1.
2.
3.
Greer Hunter R. Miller Kristen Samay Sadaf Nellan Anandani Green Adam L. 《Journal of neuro-oncology》2022,159(2):301-308
Journal of Neuro-Oncology - The role of white blood cells (WBC) in the pediatric central nervous system (CNS) tumor microenvironment is incompletely defined. We hypothesized that the WBC profile in... 相似文献
4.
Ha Audrey Y. Do Bao H. Bartret Adam L. Fang Charles X. Hsiao Albert Lutz Amelie M. Banerjee Imon Riley Geoffrey M. Rubin Daniel L. Stevens Kathryn J. Wang Erin Wang Shannon Beaulieu Christopher F. Hurt Brian 《Journal of digital imaging》2022,35(3):524-533
Journal of Digital Imaging - Scoliosis is a condition of abnormal lateral spinal curvature affecting an estimated 2 to 3% of the US population, or seven million people. The Cobb angle is the... 相似文献
5.
Moreira Daniel C. Venkataraman Sujatha Subramanian Apurva Desisto John Balakrishnan Ilango Prince Eric Pierce Angela Griesinger Andrea Green Adam Eberhardt Charles G. Foreman Nicholas K. Vibhakar Rajeev 《Journal of neuro-oncology》2020,147(3):531-545
Journal of Neuro-Oncology - MYC-driven medulloblastomas are highly aggressive childhood tumors with dismal outcomes and a lack of new treatment paradigms. We identified that targeting replication... 相似文献
6.
Heather G. Lyu MD Adil H. Haider MD MPH Adam B. Landman MD MS MIS MHS Chandrajit P. Raut MD MSc 《Cancer》2019,125(17):2926-2934
The rarity and heterogeneity of sarcomas make performing appropriately powered studies challenging and magnify the significance of large databases in sarcoma research. Established large tumor registries and population-based databases have become increasingly relevant for answering clinical questions regarding sarcoma incidence, treatment patterns, and outcomes. However, the validity of large databases has been questioned and scrutinized because of the inaccuracy and wide variability of coding practices and the absence of clinically relevant variables. In addition, the utilization of large databases for the study of rare cancers such as sarcoma may be particularly challenging because of the known limitations of administrative data and poor overall data quality. Currently, there are several large national cancer databases, including the Surveillance, Epidemiology, and End Results database, the National Cancer Data Base of the American College of Surgeons and the American Cancer Society, and the National Program of Cancer Registries of the Centers for Disease Control and Prevention. These databases are often used for sarcoma research, but they are limited by their dependence on administrative or billing data, the lack of agreement between chart abstractors on diagnosis codes, and the use of preexisting documented hospital diagnosis codes for tumor registries, which lead to a significant underestimation of sarcomas in large data sets. Current and future initiatives to improve databases and big data applications for sarcoma research include increasing the utilization of sarcoma-specific registries and encouraging national initiatives to expand on real-world, evidence-based data sets. 相似文献
7.
Amy Downing Penny Wright Luke Hounsome Peter Selby Sarah Wilding Eila Watson Richard Wagland Paul Kind David W Donnelly Hugh Butcher James W F Catto William Cross Malcolm Mason Linda Sharp David Weller Galina Velikova Eilis McCaughan Rebecca Mottram Adam W Glaser 《The lancet oncology》2019,20(3):436-447
8.
Achim Rosemann Adam Balen Brigitte Nerlich Christine Hauskeller Margaret Sleeboom‐Faulkner Sarah Hartley Xinqing Zhang Nick Lee 《The Hastings Center report》2019,49(3):30-42
A central problem for the international governance of heritable germline gene editing is that there are important differences in attitudes and values as well as ethical and health care considerations around the world. These differences are reflected in a complicated and diverse regulatory landscape. Several publications have discussed whether reproductive uses would be legally permissible in individual countries and whether clinical applications could emerge in the context of regulatory gaps and gray areas. Systematic comparative studies that explore issues related to the governance of this technology from different national and international perspectives are needed to address the lack of knowledge in this area. In this research report, we contribute to filling this gap by presenting views of stakeholders in the United Kingdom on challenges to the governance of heritable genome editing. We present findings from a multistakeholder study conducted in the United Kingdom between October 2016 and January 2018 and funded by the Wellcome Trust. This research included interviews, literature analysis, and a workshop. We involved leading U.K. scientists, in vitro fertilization clinicians, and representatives from regulatory bodies, patient organizations, and other civil societal organizations, as well as fertility companies. Part one of this article explores stakeholder perceptions of possible global developments in heritable genome editing and associated risks and governance challenges. Part two presents a range of policy options that were generated during the workshop in relation to the challenges discussed in part one. 相似文献
9.
10.
Adam Wagstaff 《Health economics》2019,28(6):765-781
In the “basic” approach, medical expenses are catastrophic if they exceed a prespecified percentage of consumption or income; the approach tells us if expenses cause a large percentage reduction in living standards. The ability‐to‐pay (ATP) approach defines expenses as catastrophic if they exceed a prespecified percentage of consumption less expenses on nonmedical necessities or an allowance for them. The paper argues that the ATP approach does not tell us whether expenses are large enough to undermine a household's ability to purchase nonmedical necessities. The paper compares the income‐based and consumption‐based variants of the basic approach, and shows that if the individual is a borrower after a health shock, the income‐based ratio will exceed the consumption‐based ratio, and both will exceed the more theoretically correct Flores et al. ratio; whereas if the individual continues to be a saver after a health shock, the ordering is reversed and the income‐based ratio may not overestimate Flores et al.'s ratio. Last, the paper proposes a lifetime money metric utility (LMMU) approach defining medical expenses as catastrophic in terms of their lifetime consequences. Under certain assumptions, the LMMU and Flores et al. approaches are identical, and neither requires data on how households finance their medical expenses. 相似文献